Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 6/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.46 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23208 | 0.89 | TACR1 (0.43) | DHODHTACR1MRGPRX4KDM4ERAB9A | |
| SCHEMBL21613 | 0.84 | DHODH (0.46) | DHODHEIF4A1AKR1B1 | |
| SCHEMBL21973 | 0.84 | DHODH (0.46) | DHODHEIF4A1AKR1B1KDM4ETDP1 | |
| SCHEMBL20614 | 0.81 | DHODH (0.48) | DHODHEIF4A1KDM4ETDP1 | |
| SCHEMBL21596 | 0.81 | KCNQ3 (0.45) | TACR1PTGER4KDM4E | |
| SCHEMBL20784 | 0.80 | DHODH (0.51) | DHODHEIF4A1KDM4E | |
| SCHEMBL23433 | 0.79 | DHODH (0.46) | DHODHEIF4A1MRGPRX4KDM4E | |
| SCHEMBL22161 | 0.78 | TACR1 (0.43) | TACR1KDM4E | |
| Hydrochloric Acid SCHEMBL22807 | 0.78 | DHODH (0.49) | DHODHEIF4A1KDM4E | |
| SCHEMBL1721616 | 0.76 | DHODH (0.46) | DHODHEIF4A1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609085-A1 | SUBSTITUTED QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-8445512-B2 | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20120053204-A1 | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| WO-2012025238-A1 | SUBSTITUTED QUINOLINE-3-CARBOXAMIDES AS KCNQ2/3 MODULATORS | Grünenthal GmbH (DE) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053204-A1 | Substituted quinoline-3-carboxamides as KCNQ2/3 modulators | KCNQ1, KCNQ2, KCNQ3 | DHODH 3082/4885TACR1 2506/4885EIF4A1 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.